Hutchmed (China) Limited (HCM) has released an update.
HUTCHMED (China) Limited is set to present new and updated data on its cancer treatment compounds at AACR Annual Meeting 2024, including promising preclinical results for leukemia inhibitor HMPL-506 and the novel CD38-targeting antibody-drug conjugate HMPL-A067. The company, known for its targeted therapies and immunotherapies, also plans to reveal early clinical data for other cancer drugs in its pipeline, highlighting its ongoing commitment to advancing cancer treatment.
For further insights into HCM stock, check out TipRanks’ Stock Analysis page.
